OWC Pharmaceuticals Corp to Present at Israeli Advanced Technology Industry's BioMed Conference

Selected To Present at the Start-ups Hall Booth #80

Apr 26, 2016, 08:00 ET from OWC Pharmaceutical Research Corp.

PETACH TIKVA, Israel, April 26, 2016 /PRNewswire/ --

 

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that it was selected to present at the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference (the "Conference").

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )

The Conference is a part of Israel's 15th National Life Sciences and Technology Week, and is being held May 24th to 26th at the David Intercontinental Hotel in Tel Aviv, Israel. The Company is currently scheduled to present at Booth #80 on the 24th .

The Biomed conference is the preeminent event for the Israeli life sciences industry, attracting leading members of the healthcare industry from around the globe. It comprises group discussions, panel presentations, product demonstrations and networking opportunities, all designed to encourage business collaborations. Attendees are able to experience firsthand the entrepreneurial spirit which is a basis of Israel's vibrant life sciences community. Prior conferences have hosted over 6,000 industry senior executives, scientists, and engineers, including approximately 1,000 participants from over 45 countries and in excess of 4,500 one-on-one meetings.

Ziv Turner, OWC Israel CEO stated, "We are so proud to have been selected by IATI to participate in BioMed. This is the biggest and most established annual meeting of the Israeli life science industry. The conference attracts investors and companies from around the world who are looking for innovation and ground breaking technology, providing us with the opportunity to meet one on one with potential investors, strategic partners and collaborators."

About OWC Pharmaceutical Research Corp.    

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).  For more information, visit: http://www.owcpharma.com/

Notice Regarding Forward-Looking Statements   

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659

In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909


SOURCE OWC Pharmaceutical Research Corp.